Ulrich Lücking

10PUBLICATIONS
25CO-AUTHORS
Molecular medicineMolecular targetsOrganometallic chemistry
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Jun 05, 2023
European Medicinal Chemistry Leaders in Industry (EMCL) - On the Status and Future of Medicinal Chemistry Research in Europe.

Amjad Ali, Marcus Bauser, Sophie Bertrand

|Aug 24, 2021
BAY-8400: A Novel Potent and Selective DNA-PK Inhibitor which Shows Synergistic Efficacy in Combination with Targeted Alpha Therapies.

Markus Berger, Lars Wortmann, Philipp Buchgraber

|Jul 15, 2021
Changing for the Better: Discovery of the Highly Potent and Selective CDK9 Inhibitor VIP152 Suitable for Once Weekly Intravenous Dosing for the Treatment of Cancer.

Ulrich Lücking, Dirk Kosemund, Niels Böhnke

|Jun 06, 2020
Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models.

Ulrich Lücking, Lars Wortmann, Antje M Wengner

|May 20, 2020
Synthesis of Highly Enantioenriched Sulfonimidoyl Fluorides and Sulfonimidamides by Stereospecific Sulfur-Fluorine Exchange (SuFEx) Reaction.

Stephanie Greed, Edward L Briggs, Fahima I M Idiris

|Jan 22, 2020
Increasing Complexity: A Practical Synthetic Approach to Three-Dimensional, Cyclic Sulfoximines and First Insights into Their in Vitro Properties.

Emilie Boulard, Vivien Zibulski, Luisa Oertel

Pageof 2

Frequent Collaborators

3 joint publications

Lars Wortmann

2 joint publications

Robert Stockman

2 joint publications

Julien Lefranc

2 joint publications

Knut Eis